OTC Angiotensin II Receptor Blocker Qualification System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for making angiotensin II receptor blockers available over-the-counter face challenges due to inappropriate patient selection and medication use, leading to safety concerns and ineffective treatment of hypertension, as patients often fail to self-select and use these medications responsibly.
Innovation Solution
A system and method for qualifying human subjects for over-the-counter delivery of angiotensin II receptor blockers, involving surveys and filters to assess eligibility, providing warnings for risk factors, and ensuring acknowledgment of warnings before dispensing the medication, to ensure safe and responsible use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If angiotensin II receptor blockers are made available over-the-counter, then accessibility and availability of hypertension treatment is improved, but patient safety and appropriate medication use deteriorates due to inability to properly self-select and use the medication responsibly
Solution Approach 1:
A digital qualification system acts as an intermediary between the patient and the medication. The system includes a digital tool that assesses patient eligibility through questionnaire responses, evaluates contraindications, and determines whether the patient is appropriate for OTC angiotensin II receptor blocker use. This intermediary ensures that only qualified patients receive the medication, maintaining safety while enabling OTC accessibility.
2Productivity
If prescription requirements are removed for angiotensin II receptor blockers, then ease of access to treatment is improved, but risk of inappropriate use and adverse events increases
Solution Approach 1:
The system performs preliminary assessment and qualification actions before the patient receives the medication. A digital tool evaluates patient responses against established criteria, identifies contraindications in advance, and qualifies or disqualifies patients before they can access the OTC angiotensin II receptor blocker. This preliminary action prevents inappropriate use while maintaining efficient access for qualified patients.
3Ease of operation
If self-medication is enabled without qualification assessment, then ease of operation is improved, but measurement precision of patient eligibility deteriorates
Solution Approach 1:
The digital qualification system implements feedback mechanisms where patient responses to questionnaire items are systematically evaluated against predetermined criteria. The system provides feedback to patients about their eligibility status and guides them through the qualification process, ensuring accurate assessment of their suitability for OTC angiotensin II receptor blocker use while maintaining ease of operation.
Data Source
AI summary
A method is provided for lowering blood pressure in a subject in need thereof by administering an angiotensin II receptor blocker pharmaceutical composition to a subject qualified for over-the-counter access to the angiotensin II receptor blocker pharmaceutical composition. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition includes azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan. In some embodiments, the angiotensin II receptor blocker pharmaceutical composition comprises an active ingredient that is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof.